Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis Sells 4,160 Shares

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 4,160 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $185,536.00. Following the transaction, the chief financial officer now owns 89,237 shares in the company, valued at $3,979,970.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 9th, Adam Laponis sold 856 shares of Twist Bioscience stock. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36.

Twist Bioscience Trading Down 0.3 %

Twist Bioscience stock opened at $45.40 on Friday. Twist Bioscience Co. has a 12-month low of $15.85 and a 12-month high of $60.90. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The firm has a 50 day moving average of $43.69 and a 200 day moving average of $45.54.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. grew its position in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird raised their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.